Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

DISEASE CHARACTERISTICS: * Histologically confirmed melanoma * Metastatic disease * Measurable or evaluable non-CNS disease * Measurable disease, defined as a unidimensionally measurable lesion as determined by physical exam, x-ray, CT scan, MRI, or other radiographic procedure * Evaluable disease, defined as a lesion that can be seen radiographically but is not unidimensionally measurable * Previously irradiated lesions with documented progression are allowed provided there are no other sites of metastatic disease * No active brain metastases * Previously treated, responding brain metastases allowed, provided there is measurable disease outside of the CNS * At least 3 weeks since prior chemotherapy and 6 weeks since prior radiotherapy for CNS disease PATIENT CHARACTERISTICS: Inclusion criteria: * ECOG performance status 0-2 * Life expectancy ≥ 3 months * ANC ≥ 1,200/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min * Bilirubin ≤ 3.0 mg/dL * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * EKG with no evidence of serious arrhythmia or recent myocardial infarction Exclusion criteria: * Active infection * Chronic underlying immunodeficiency disease * Other serious concurrent illness * Other forms of cancer within 5 years of initial diagnosis except nonmelanoma skin cancer and cervical cancer * Congestive heart failure or myocardial infarction within the past 6 months PRIOR CONCURRENT THERAPY: Inclusion criteria: * See Disease Characteristics * At least 6 weeks since prior radiotherapy * More than 4 weeks since prior surgery * Prior biologic therapy allowed Exclusion criteria: * Prior cytotoxic agents * Prior sorafenib tosylate, bevacizumab, or oxaliplatin * Concurrent biological therapy, except growth factors for anemia, neutropenia, or thrombocytopenia * Concurrent radiotherapy, chemotherapy, or surgery